BEZETABART DEBOTANSINE
UNII 0D8BWL78LD

Substance Identification & Data

This profile provides standardized clinical and technical data for Bezetabart Debotansine, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 0D8BWL78LD.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2763746-70-7 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

0D8BWL78LD

CAS Registry Number

2763746-70-7

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

BEZETABART DEBOTANSINE

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C148066

National Cancer Institute reference terminology for clinical and research data.

INN ID

12652

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Bezetabart Debotansine

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Bezetabart Debotansine. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Bezetabart Debotansine

Common Names & Synonyms

ANTI-CD74 ANTIBODY-DRUG CONJUGATE STRO-001

Bezetabart Debotansine [WHO-DD]

Gamma1 heavy chain (1-454) [VH (Homo sapiens IGHV3-30-5*03 (95.9%) -(IGHD) -IGHJ6*01 (93.8%), CDR-IMGT [8.8.16] (27-34.52-59.98-113)) (1-124) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14 (CH1R120>K(221) (125-222), hinge 1-15 (223-237), CH2 (238-347), CH3 E12 (363), M14 (365), F85.2>F (pAMF) (411) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfide with kappa light chain (1'-215') [V-KAPPA (Homo sapiens IGKV1-12*01 (92.6%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (28'-33'.51'-53'.90'-98')) (1'-108') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (154'), V101 (192') (109'-215')]; dimer (233-233'':236-236'')-bisdisulfide; produced by a cell-free protein expression system based on Escherichia coli lysate, non-glycosylated; substituted at C-4 of the L-phenylalanyl residues 411 and 411'' with {8-[(2S)-1-{[(14S,16S,2R,32S,33S,4S,10E,12E,14R)-86-chloro-14-hydroxy-85 ,14-dimethoxy-2,33,7,10-tetramethyl-12 ,6-dioxo-7-aza-1(6,4)-[1,3]oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl]oxy}-2,3,9-trimethyl-1,4,8,24-tetraoxo-12,15,18,21-tetraoxa-3,9,25-triazaoctacosan-28-oyl]-8,9-dihydro-1H(or 3H)- dibenzo[b,f][1,2,3]triazolo[4,5-d]azocin-1(or 3)-yl}methyl (debotansine) groups

Immunoglobulin G1, anti-(human CD74 antigen) (human monoclonal SP7219 γ1-chain), disulfide with human monoclonal SP7219 κ-chain, dimer, 411,411′-bis[4-[[8-(3-amino-1-oxopropyl)-8,9-dihydroxy-1H(or 3H)-dibenzo[b,f]-1,2,3-triazolo[4,5-d]azocin-1(or 3)-yl]methyl]-L-phenylalanine], amide with N2′-(20-carboxy-6-methyl-1,5-dioxo-9,12,15,18-tetraoxa-6-azaeicos-1-yl)-N2′-deacetylmaytansine

Immunoglobulin G1-kappa, anti-[Homo sapiens CD74 (major histocompatibility complex class II invariant chain)], monoclonal antibody, conjugated at C-4 of two specific phenylalanine residues with N2' -deacetylmaytansine via a non cleavable linker

STRO-001, A SITE-SPECIFIC ANTI-CD74 ANTIBODY-DRUG CONJUGATE

bezetabart debotansine [INN]